Entera Bio Ltd.ENTXEarnings & Financial Report
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral formulations of biologics and large-molecule therapies traditionally administered via injection. Its core pipeline targets treatments for rare diseases, metabolic disorders, and autoimmune conditions, serving patient populations across global markets.
ENTX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-3.0M
Net Profit
$-3.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.06
Entera Bio Ltd. Q4 FY2025 Financial Summary
Entera Bio Ltd. reported revenue of $0 for Q4 FY2025, with a net profit of $-3.0M (down 27.9% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $3.0M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-3.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Entera Bio Ltd. Annual Revenue by Year
Entera Bio Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $42.0K).
Entera Bio Ltd. Quarterly Revenue & Net Profit History
Entera Bio Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-3.0M | N/A |
| Q3 FY2025 | $0 | — | $-3.2M | N/A |
| Q2 FY2025 | $0 | — | $-2.7M | N/A |
| Q1 FY2025 | $42.0K | — | $-2.6M | -6111.9% |
| Q4 FY2024 | $82.0K | — | $-2.4M | -2875.6% |
| Q3 FY2024 | $42.0K | — | $-3.0M | -7192.9% |
| Q2 FY2024 | $57.0K | — | $-2.1M | -3763.2% |
| Q1 FY2024 | $0 | — | $-2.0M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $57000 | $42000 | $82000 | $42000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.2M | $10.0M | $7.7M | $9.4M | $21.6M | $19.7M | $17.4M | $16.0M |
| Liabilities | $1.4M | $1.5M | $1.3M | $1.3M | $2.2M | $2.4M | $2.2M | $2.9M |
| Equity | $8.9M | $8.5M | $6.5M | $8.1M | $19.4M | $17.3M | $15.2M | $13.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.3M | $-2.2M | $-1.5M | $-1.4M | $-1.6M | $-2.5M | $-1.8M |